Top advisor warns against arrogance towards EU
Tone down the arrogance towards EU’s regulatory authorities, when it comes to approval of new drugs and medical equipment. It could backfire, says Steffen Thirstrup, who knows the system better than most people. He also warns against common errors that he sometimes sees from inexperienced companies.
by Henrik Tüchsen
Biotech and pharmaceutical companies should shelve the arrogance when applying for approval of new drugs or seeking the all clear to go ahead with clinical testing in the EU. EU’s medicines authorities, EMA, take offence to being looked down upon as a less important agency than the American FDA.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
